CAS 1392116-14-1

JD-5037

CAS: 1392116-14-1

(S)-2-((((S)-3-(4-Chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(4-chlorophenylsulfonamido)methylene)amino)-3-methylbutanamide

Fórmula: C₂₇H₂₇Cl₂N₅O₃S

Pureza: 98%

Peso molecular: 572.51

Ref: IN-DG767437

JD-5037

CAS: 1392116-14-1

Fórmula: C₂₇H₂₇Cl₂N₅O₃S

Pureza: 98%

Cor e Forma: Solid

Peso molecular: 572.5060

Ref: IN-DA01EONN

JD-5037

CAS: 1392116-14-1

JD-5037

Fórmula: C₂₇H₂₇Cl₂N₅O₃S

Pureza: ≥98%

Peso molecular: 572.51

Ref: 54-BUP09512

JD-5037

CAS: 1392116-14-1

JD-5037 is a novel, peripherally restricted CB1R antagonist with an IC50 of 1.5 nM.

Fórmula: C₂₇H₂₇Cl₂N₅O₃S

Pureza: 99.54% - 99.84%

Cor e Forma: Solid

Peso molecular: 572.51

Ref: TM-T4453

JD 5037

CAS: 1392116-14-1

JD 5037 is a monoclonal antibody that inhibits the binding of endocannabinoids to their receptors. This drug has been shown to be effective in animal models of obesity, diabetes, and cancer. JD 5037 binds to the CB2 receptor and antagonizes the effects of endocannabinoids by preventing them from binding. The high affinity of this drug for the CB2 receptor may be due to its tautomeric structure. This drug also appears to have potential as an anticancer agent due to its ability to bind and inhibit rapamycin complex-1 (raptor) and cb2 receptor.

Fórmula: C₂₇H₂₇C₁₂N₅O₃S

Pureza: Min. 95%

Peso molecular: 645.73 g/mol

Ref: 3D-FJ166461